IDEXX Laboratories Exceeds Q3 Estimates and Raises 2026 Revenue Guidance
IDEXX Laboratories (IDXX) reported third-quarter financial results that surpassed both top-line and bottom-line analyst expectations. The company posted non-GAAP earnings per share of $3.96, exceeding estimates by $0.25, while revenue reached $1.21 billion, representing a 10% year-over-year increase and beating consensus by $20 million. Driven by strong recurring revenue performance within its Companion Animal Diagnostics segment, the company has proactively raised its full-year 2026 revenue guidance. The new projected range of $4,741 million to $4,767 million sits above previous market expectations, signaling sustained growth momentum in its core diagnostic business.
Tickers: $IDXX
Topics: diagnostics revenue earnings beat guidance increase revenue growth